New drug shows promise against platinum resistant ovarian cancerOctober 10th, 2010 - 1:39 pm ICT by ANI
Washington, Oct 10 (ANI): An international research group has reported that a drug being developed as a treatment for ovarian cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial.
Dr Ursula Matulonis from Dana-Farber Cancer Institute in the USA reported the results of the single-agent trial of the drug, called MLN8237, in a poster at the 35th Congress of the European Society for Medical Oncology (ESMO).
MLN8237 selectively inhibits an enzyme known as Aurora A kinase, which is a member of a family of kinase enzymes involved in normal cell division. Researchers have found that Aurora A kinase is over-expressed in some cancer cells, leading to growth of cancers.
“In epithelial ovarian cancer, Aurora A kinase has been reported to be frequently upregulated or overexpressed, and associated with worse clinical outcome,” Dr Matulonis said.
“This is why an effective Aurora A Kinase inhibitor is a potential new therapy to be used alone or in combination with other standard agents such as paclitaxel.”
In addition to ovarian cancer, the Aurora A kinase gene is amplified or overexpressed, or both, in other cancers including colon, breast, pancreatic, and bladder cancers, as well as certain lymphomas, leukemias and myeloma.
Unlike other aurora kinase inhibitors currently being studied, MLN8237 selectively targets aurora A Kinase and can be administered orally, Dr Matulonis said.
In the current study, American, French, Italian and Polish researchers treated 31 patients whose cancer was resistant or refractory to platinum-based chemotherapy and who had tried at least three other therapies. Twenty-five patients had ovarian cancer, 5 had primary peritoneal cancer, and one had Fallopian tube carcinoma.
“The patients enrolled to this study all had progression after platinum-containing regimens which is the mainstay of ovarian cancer treatment,” Dr Matulonis said. “Patients with ‘platinum resistant’ recurrent ovarian cancer represent a large unmet medical need.”
The patients received MLN8237 in 21-day cycles: seven days of twice-daily 50mg treatment, followed by a 14-day break. Three patients had a partial response to the treatment, and 5 had stable disease that was sustained for at least four 21-week cycles, the researchers report.
“The most important finding from this study was the fact that MLN8237 demonstrates single-agent activity in ovarian cancer with encouraging durable disease control in some patients,” Dr Matulonis said. (ANI)
- New experimental drug slows down growth of ovarian cancer - Apr 16, 2011
- New drug shows promise against ovarian and breast cancer - Aug 13, 2010
- 'Smart' new drug shows promise in ovarian cancer - Nov 09, 2010
- Motor protein that blocks ovarian tumor growth found - Apr 27, 2011
- How ovarian cancer resists chemotherapy - Mar 03, 2011
- New drug combo may treat newly diagnosed cancer patients - Dec 10, 2010
- Gene makes ovarian cancer resistant to chemotherapy - Mar 03, 2011
- Cancer drugs offer new hope for Crohn's disease and sarcoidosis - Dec 01, 2010
- Drug discovery combats ovarian cancer - Jun 05, 2011
- Boffins discover key enzyme in DNA repair pathway - Jul 30, 2010
- Potential new target for treatment of ovarian cancer identified - Aug 17, 2010
- Blocking DNA repair protein likely to make cancer therapy safer - Jun 02, 2010
- New gene may lead to personalized ovarian cancer treatment - Dec 09, 2009
- New genetic marker of ovarian cancer risk discovered - Jul 21, 2010
- New colon cancer marker identified - Mar 26, 2011
Tags: aurora kinase, bladder cancers, cancer cells, cancer treatment, clinical outcome, dana farber cancer, dana farber cancer institute, epithelial ovarian cancer, fallopian tube, farber cancer institute, five patients, international research group, kinase inhibitor, kinase inhibitors, leukemias, medical oncology, ovarian cancer, paclitaxel, polish researchers, primary peritoneal cancer